Huvepharma opened its new fermentation plant Sept. 16 in Peshtera in southern Bulgaria. The new plant has a total fermentation capacity of 3,500 cu. m, enabling the company to increase its total production capacity by 30% and allowing it to ferment its entire current product portfolio in one location, the announcement said.
Huvepharma managing director Eddy Piron said, "The increased capacity in our new production facility in Peshtera allows us to meet our ambitious and continuous growth plans to expand our market share in the field of fermented products, including coccidiostats, antibiotics, enzymes, probiotics and human health APIs [active pharmaceutical ingredients]."
According to Huvepharma, more than 150 new jobs have been created in Peshtera.
"We have invested 150 million euros in our European production facilities, despite fierce competition from other production sites around the world," Piron added. Since Bulgaria is a member of the European Union, he said all of the company's plants have been approved by European regulatory authorities and operate under European good manufacturing practices guidelines and additionally have U.S. Food & Drug Administration approval, "making us an attractive and internationally competitive production partner."
Huvepharma, headquartered in Sofia, Bulgaria, is a fast-growing global pharmaceutical company with a focus on developing, manufacturing and marketing of human and animal health products. The privately owned company also manufactures and markets enzymes for food, feed and industrial applications.
Huvepharma's manufacturing subsidiary, Biovet, is headquartered in Peshtera and has three production units in Bulgaria as well as two facilities in the U.S.
Huvepharma has representative offices and subsidiaries in Bulgaria, Belgium, Poland, China, Taiwan, Thailand, the U.S., Russia, India, Brazil and Turkey.